Descrizione del progetto
Intervenire sulle sottopopolazioni preesistenti di cellule di cancro ovarico resistenti ai farmaci
Il cancro ovarico è il quinto tipo di cancro più mortale in Europa. La chemioterapia standard è efficace nell’eliminare le masse tumorali, ma la maggior parte delle pazienti con diagnosi di cancro ovarico avanzato muore dopo l’insorgenza di nuove lesioni provenienti dalle piccole sottopopolazioni di cellule resistenti ai farmaci sopravvissute. Il progetto RESIST3D, finanziato dall’UE, sta sviluppando nuove direzioni nell’oncologia di precisione attaccando le piccole sottopopolazioni pre-esistenti di cellule resistenti ai farmaci invece della massa tumorale. La ricerca utilizza organoidi di cancro ovarico 3D derivati da pazienti per cercare nuove strategie volte a sradicare le cellule tumorali resistenti ai farmaci. I modelli per la profilazione della risposta ai farmaci aiuteranno nell’identificazione di un trattamento che eradichi le cellule resistenti ai farmaci preesistenti, da applicare in combinazione con la chemioterapia standard.
Obiettivo
Ovarian cancer is the fifth most deadly cancer type among women in Europe. Despite the fact that standard chemotherapy is usually effective in eliminating bulk tumour mass, thereby inducing remission, most patients diagnosed with advanced ovarian cancer die from the disease, as relapsed lesions emerge from small subpopulations of surviving drug-resistant cells.
Precision medicine aims to improve cancer care through tailoring individualized therapies based on genomic or functional profiling of human cancers. However, as these approaches are usually performed on bulk tumour cells, the small pre-existing drug-resistant cell subpopulations remain untargeted.
In the RESIST3D project, I will utilize ovarian cancer organoids – a patient-derived, three-dimensional cell cultures – to search for new strategies to eradicate drug-resistant cancer cells. I will use two organoid models developed for the same patient – one model derived from tumour material taken before chemotherapeutic treatment and one from a post-treatment sample, typically enriched in drug-resistant cells. I will further enrich the organoids in quiescent, drug-resistant cells by maintaining them in physiologic-like culture medium. I will then apply the models for drug-response profiling in order to identify agents that eradicate pre-existing drug-resistant cells, which could be combined with standard chemotherapy. Finally, I will assess whether the selected combinations prevent relapses in patient-derived xenograft mouse models.
RESIST3D sets a new direction in precision cancer medicine, as it focuses on targeting small pre-existing subpopulations of drug-resistant cells rather than bulk tumour mass. Through combining organoid model, paired samples for each patient and physiologic culture conditions, I expect to identify new ways to target drug-resistant ovarian cancer cells. Moreover, RESIST3D will provide me with new research expertise and a scientific network that will enhance my research career.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinatore
1165 Kobenhavn
Danimarca